American Society of Hematology

Figure 5.

$Figure 5. Analysis of CD25+ HTLV-I–infected cells. (A) FACS analysis of the presence of CD25 marker expression from CD25+ and CD25– sorted cells. (B) Telomerase activity detected by TRAP assay in CD25+ and CD25– fractions isolated from an HTLV-I donor and ATL PBMCs. (C) Integrated HTLV-I proviral DNA was detected by PCR using primers in the tax coding region. GAPDH was used as amplification control to ensure proper quality and quantity of extracted DNAs. (D) Staining control of PBMCs in presence or absence of FITC-telomere probe. (E) In situ hybridization of FITC-conjugated telomere probe (top) and DAPI (4′6-diamidino-2-phenylindole 2HCl) (bottom).$

Analysis of CD25⁺HTLV-I–infected cells. (A) FACS analysis of the presence of CD25 marker expression from CD25⁺ and CD25– sorted cells. (B) Telomerase activity detected by TRAP assay in CD25⁺ and CD25– fractions isolated from an HTLV-I donor and ATL PBMCs. (C) Integrated HTLV-I proviral DNA was detected by PCR using primers in the tax coding region. GAPDH was used as amplification control to ensure proper quality and quantity of extracted DNAs. (D) Staining control of PBMCs in presence or absence of FITC-telomere probe. (E) In situ hybridization of FITC-conjugated telomere probe (top) and DAPI (4′6-diamidino-2-phenylindole 2HCl) (bottom).

This Feature Is Available To Subscribers Only